William Blair analyst Myles Minter downgraded Alector (ALEC) to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm needs to see clinical data for Alector’s platform to evaluate its other programs.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
- Alector discontinues extension portion of INFRONT-3 trial